SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS
Daichi Inoue(Tokyo University of Science), Toshio Kitamura(National Agriculture and Food Research Organization), Jiro Kitaura(Juntendo University), Toshiya Inaba(Hiroshima University), Yuka Harada(Tokyo Metropolitan Komagome Hospital), Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center), Saburo Horikawa(The University of Tokyo), Katsuhiro Togami(Dana-Farber Cancer Institute), Hironori Harada(Tokyo University of Pharmacy and Life Sciences), Reina Nagase(The University of Tokyo), Yasutaka Hayashi(Tokyo Medical and Dental University), Hirotaka Matsui(Hiroshima University), J-B Micol(Memorial Sloan Kettering Cancer Center), Kimihito C. Kawabata(The University of Tokyo), Makoto Saika(The University of Tokyo), Akiko Nagamachi(Hiroshima University)
Cited by 100
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k